GSK’s Lamictal Gets New Approval

The FDA has approved a new use of GlaxoSmithKline’s anti-seizure medicine, Lamictal Tablets, for the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, also known as “grand mal” seizures—one of the most serious forms of epilepsy. With this new indication, Lamictal can now be used as add-on therapy to treat PGTC seizures in children aged 2 and older as well as adults. This marks GSK’s fifth FDA approval for Lamictal in epilepsy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters